Northpointe Capital’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-290,649
Closed -$5.46M 175
2017
Q1
$5.46M Sell
290,649
-168,343
-37% -$2.65M 0.6% 61
2016
Q4
$6.68M Buy
458,992
+59,688
+15% +$812K 0.66% 55
2016
Q3
$5.3M Buy
+399,304
New +$4.63M 0.55% 62
2016
Q2
Sell
-292,350
Closed -$3.27M 191
2016
Q1
$3.27M Buy
292,350
+44,865
+18% +$459K 0.41% 91
2015
Q4
$2.64M Hold
247,485
0.35% 111
2015
Q3
$2.64M Buy
247,485
+35,442
+17% +$432K 0.34% 112
2015
Q2
$2.51M Buy
212,043
+106,363
+101% +$1.23M 0.3% 120
2015
Q1
$1.01M Sell
105,680
-85,035
-45% -$879K 0.11% 210
2014
Q4
$1.95M Buy
+190,715
New +$1.66M 0.23% 147

Other funds holding ACLS

Northpointe Capital's ACLS Position: Q2 2017 in Review

Northpointe Capital sold out of Axcelis (ACLS) in Q2 2017, closing a stake of 290,649 shares — an estimated $5.46M sold.

Northpointe Capital first reported a position in ACLS in Q4 2014 and held it in 9 quarters. The position peaked at $6.68M in Q4 2016. 130 funds tracked by Wall St. Rank hold ACLS as of Q2 2017.

  • Northpointe Capital reported no remaining Axcelis position as of Q2 2017 after selling out during the quarter.
  • Northpointe Capital sold 290,649 Axcelis shares in Q2 2017, an estimated $5.46M.
  • Northpointe Capital first reported a position in Axcelis in Q4 2014 and held it in 9 quarters.
  • Northpointe Capital's Axcelis position peaked at $6.68M in Q4 2016.
  • 130 funds tracked by Wall St. Rank held Axcelis as of Q2 2017.

Based on Northpointe Capital's 13F filing for Q2 2017, filed 3 Aug 2017.